-
Our Vision is to improve healthcare as a global provider of innovative and reliable diagnostic tests. -
Our Mission is to identify and develop novel patentable diagnostic markers and technologies which can be commercialised to meet clinical needs, both in the laboratory and at the point of care. -
We will collaborate with partners, create branded products and identify complementary businesses which support our objective of continuing to grow as a respected and profitable healthcare company. -
Our Values include meeting all current and future regulatory, quality and environmental standards appropriate for our industry and the countries in which we operate.
Non-Executive Directors
 |
John Brown PhD MBA FRSE John joined the Board in March 2009 and became Chairman of the Group in 2010. He has extensive experience in the life sciences sector. He is Chairman of BTG plc and CXR Biosciences Ltd and a non-executive Director of Vectura Group plc, and was a Director of Cambridge Antibody Technology plc until its acquisition by AstraZeneca. In the public sector he Chairs the Roslin Foundation and the Life Sciences Industry Advisory Board and is a non-executive director of the Technology Strategy Board. He is an advisor to several private equity and venture capital funds, a Fellow of the Royal Society of Edinburgh and Honorary Professor of the University of Edinburgh. Until Dec 2003, John was Chief Executive of Acambis plc, a leading producer of vaccines to treat and prevent infectious disease. Dr Brown joined Acambis as Finance Director in 1995 and was appointed CEO in 1997. John is Chairman of the Nomination Committee of Axis -Shield. |
Axis-Shield Directors and Senior Management
 |
John Brown PhD MBA FRSE Non-Executive Chairman |
 |
Erling M H Sundrehagen MD, MSc, PhD Chief Scientific Officer |
 |
David Bond CA Group Financial Controller |
 |
Kjersti Grimsrud MSc, Biotechnology Managing Director, Point-of-Care Division |
 |
Colin King MBA Site Director, Laboratory Division |
 |
George Zajicek BPharm, |
